Johnson & Johnson Acquires Halda Therapeutics to Advance Cancer Treatments
Johnson & Johnson has completed its $3.05 billion acquisition of Halda Therapeutics, a biotech company with a novel RIPTAC platform for developing targeted oral therapies for solid tumors, including prostate cancer, aiming to revolutionize cancer treatment and expand its oncology portfolio.